Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients undergoing left main PCI for acute coronary syndrome (ACS). However, though this strategy does reduce thrombotic events and mortality, it also causes undesirable bleeding events followed by hospitalization and antiaggregation interruption for a period of time.  A feasible<a href="https://solaci.org/en/2022/03/09/acute-coronary-syndrome-what-is-safer-antiaggregant-monotherapy-or-de-escalation/" title="Read more" >...</a>

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300 million cases globally (even though the tally has been slowing down).    The vaccine continues to offer hope and, in France for instance, president Macron has doubled their efforts to vaccinate the<a href="https://solaci.org/en/2022/01/12/once-again-the-omicron-variant-tests-the-limits-of-healthcare-systems-but-with-hope/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

TICO: Age Impacts the Effect of Antiplatelet Monotherapy

The higher the age, the greater the benefit of ticagrelor monotherapy vs. dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome. This post hoc sub-analysis of the TICO study goes along the same lines as the TWILIGHT study (which we recently discussed), given that age is the most common reason for considering that a<a href="https://solaci.org/en/2022/01/11/tico-age-impacts-the-effect-of-antiplatelet-monotherapy/" title="Read more" >...</a>

The Most Relevant Articles of 2021 in Pharmacology

This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most Relevant<a href="https://solaci.org/en/2022/01/10/the-most-relevant-articles-of-2021-in-pharmacology/" title="Read more" >...</a>

The most read scientific articles of november

November’s Most Read Studies in Interventional Cardiology in solaci.org

01- Management of Abdominal Aortic Aneurysms in 2021 Abdominal aortic aneurysms (AAA) are those of >3 cm aortic diameter.  They run the risk of rupture and ensuing death by bleeding. In consequence, they are treated to repair the aneurysm before it ruptures.  Read more HERE 02- Ten Commandments for 2021 Guidelines on Valvular Heart Disease Since<a href="https://solaci.org/en/2021/12/06/novembers-most-read-studies-in-interventional-cardiology-in-solaci-org/" title="Read more" >...</a>

AHA 2021 | RAPID CABG: seguridad de ir al quirófano precozmente en un síndrome coronario agudo

AHA 2021 | RAPID CABG: Safety of Early Surgical Intervention in Acute Coronary Syndrome

Suspending ticagrelor a couple of days before surgery was non-inferior to waiting 5-6 days in terms of bleeding in patients with acute coronary syndrome (ACS) requiring myocardial revascularization surgery. Patients who waited longer had more ischemic events and longer hospitalizations. Current American guidelines recommend waiting at least 5 days before operating on patients with ACS who<a href="https://solaci.org/en/2021/11/23/aha-2021-rapid-cabg-safety-of-early-surgical-intervention-in-acute-coronary-syndrome/" title="Read more" >...</a>

SOLACI-CACI 2021 | DAPT Session

✔️ Watch again the DAPT Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 02:58 – Short versus long-term DAPT Therapy in High Risk Bleeding. Rationality and Preliminary Results of Master DAPT trial – Peter Smits. 31:20 – Rationality of long-term DAPT in Chronic Stable Angina – Ernesto Duronto. 48:14 – Selection of the best P2Y12<a href="https://solaci.org/en/2021/09/21/solaci-caci-2021-dapt-session/" title="Read more" >...</a>

ESC 2021 | Empagliflozina en insuficiencia cardíaca con función deteriorada y preservada

ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction

The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function. The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2<a href="https://solaci.org/en/2021/09/01/esc-2021-empagliflozin-in-heart-failure-with-reduced-and-preserved-ejection-fraction/" title="Read more" >...</a>

The Most Read Articles in Interventional Cardiology of July

01- Novel DES Technology Promises to Become the Next DES Generation The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Read more HERE 02- The Fellow’s Corner | 3rd Clinical Case: True Bifurcation Lesion: Which Strategy Should We Use? Here is the third Fellow’s<a href="https://solaci.org/en/2021/08/25/the-most-read-articles-in-interventional-cardiology-of-july/" title="Read more" >...</a>

¿Desescalar la doble antiagregación es el nuevo paradigma?

Dual Antiaggregation De-Escalation: A New Paradigm?

De-escalating dual antiaggregation could be the most effective strategy after acute coronary syndrome seeing as it prevents bleeding and cut down costs with no increase of ischemic events.  Balancing the effects of dual antiaggregation therapy (DAPT) in the era of potent P2Y12 inhibitors has become the cornerstone of acute coronary syndrome (ACS) management.  This meta-analysis<a href="https://solaci.org/en/2021/08/25/dual-antiaggregation-de-escalation-a-new-paradigm/" title="Read more" >...</a>